FLEXERIL (cyclobenzaprine hydrochloride) by Johnson & Johnson is cyclobenzaprine hydrochloride relieves skeletal muscle spasm of local origin without interfering with muscle function. First approved in 1977.
Drug data last refreshed 14h ago · AI intelligence enriched 5d ago
FLEXERIL (cyclobenzaprine HCl) is an oral small-molecule muscle relaxant that relieves skeletal muscle spasm of local origin by reducing tonic somatic motor activity at the brainstem level, without directly affecting the neuromuscular junction. It is ineffective for muscle spasm caused by central nervous system disease and is used as adjunctive therapy for acute musculoskeletal conditions. The drug exhibits tricyclic antidepressant-like pharmacology, including anticholinergic and sedating properties.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling contraction phase for brand teams and shift toward generic/established product support roles.
Cyclobenzaprine hydrochloride relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to central nervous system disease. Cyclobenzaprine reduced or abolished skeletal muscle hyperactivity in several animal models. Animal studies…
Worked on FLEXERIL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
Working on FLEXERIL offers limited career growth opportunities due to its LOE-approaching status and lack of active development pipeline; roles emphasize commercial efficiency, generic defense, and payer negotiation rather than innovation. This is a stable maintenance assignment suited to professionals seeking established-product expertise or market access specialization, but not ideal for those pursuing launch-phase visibility or clinical development pathways.